Netalie Nadivi
Partner @ Triventures
Netalie Nadivi is a Series A investor at Triventures focused on Health Care and Medical Device. Partnering with visionary, goal-oriented entrepreneurs with hustle
- Total investments:
- 13
- Last investment:
- Lead investor:
- 62%
Last updated:
For AI agents: llms.txt
Industries Netalie Nadivi invests in
Stages Netalie Nadivi invests in
Countries Netalie Nadivi invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 7 (54%)
- Medical Device 3 (23%)
- FinTech 2 (15%)
- Wellness 2 (15%)
- Biotechnology 2 (15%)
Stage
- Series A 3 (23%)
- Seed 2 (15%)
- Series B 2 (15%)
- Venture - Series Unknown 2 (15%)
- Convertible Note 1 (8%)
Country
- United States 5 (38%)
- Israel 2 (15%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| PayGround provides healthcare businesses of all sizes a modernized payment solution in which they can easily upload their A/R and trigger digital-first requests for payment (via a mix of email/text/U.S. Mail). Patients can make payments in just a matter of a few seconds. | $5.5M / Convertible Note / Apr 01, 2022 | ||
| The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and our proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale. Our technologies include novel sample preparation methods enablingunprecedented ultra-high enrichment of pathogen DNA for sequencing directly from clinical samples, machine learning algorithms that provide clinically actionable diagnostic results, and a world-class database of WGS and drug efficacy profiles. Day Zero Diagnostics is on a mission to transform the way infectious disease diagnostics are performed by generating the stream of real-time sequencing data required to change how we track, manage and combat infectious diseases.With an enormous unmet clinical and economic need, we are targeting bloodstream infections and sepsis for our first application. The life expectancy of a patient with septic shock is 24 hours without fast effective antibiotic treatment. However, even when successful, current diagnostics take 2-5 days to identify the pathogen AND provide its antibiotic susceptibility profile. The lack of rapid, accurate, and comprehensive diagnostics, forces physicians to “carpet bomb” patients with severe infections with powerful, yet toxic, broad-spectrum antibiotics, which is not only ineffective in many cases but can also lead to significant morbidity and mortality. Day Zero delivers a complete diagnosis, including both the species and antibiotic resistance profile, in hours vs. days, enabling the physician to use a targeted treatment on day zero of hospital admission and resulting in better patient outcomes and cost savings. | $21M / Venture - Series Unknown / Feb 09, 2022 | ||
| TailorMed is a health IT company that works with providers, pharmacies and manufacturers to reduce patient financial toxicity and create efficiencies across the patient treatment lifecycle. Our end-to-end platform applies algorithms and automations to make the co-pay assistance and free drug order processes seamless and leverages our deep data setto create actionable insights. | $20M / Venture - Series Unknown / Jun 07, 2021 | ||
| Brightside Health is a mental health care company that helps employees better navigate and manage their financial well-being. The company makes it simple and affordable to get expert, personalized treatment for depression and anxiety all from the comfort of home. Their mission is to help people lead healthy, vital, and productive lives by making iteasy and affordable to get high-quality depression and anxiety care.Brightside was founded in 2017 and is headquartered in San Francisco, California, United States. | $24M / Series A / May 28, 2021 | ||
| Grin is a comprehensive digital orthodontic platform providing teeth straightening for all types of patients with a real local orthodontist. The platform also connects patients with a real orthodontist from the convenience of their smart device. They deliver responsible care from orthodontic specialists in an easily accessible and cost-effectiveway, Grin provides patients quality care that results in an exceptional smile together with all of the modernized convenience that they expect.Grin technology, aligned with a network of local trusted orthodontists, ensures that every patient gets the right care. The platform Grin App and Grin Scope is a patent-pending technology that offers remote monitoring for a variety of orthodontic needs. The Grin experience includes high-quality self-scans with the latest teeth straightening solutions. Practitioners and patients can now use these telemedicine tools to achieve a new, more convenient treatment journey.It was founded by Dr. Adam Schulhof, Pamela Oren-Artzi, and Alon Lipnik in 2019 and is based in New York and Austin. | $10M / Seed / Apr 29, 2021 | ||
| PayGround provides healthcare businesses of all sizes a modernized payment solution in which they can easily upload their A/R and trigger digital-first requests for payment (via a mix of email/text/U.S. Mail). Patients can make payments in just a matter of a few seconds. | $3.5M / Seed / Mar 02, 2021 | ||
| Genoox develops and provides a cloud based big data platform for storing and managing genomic data. Its platform allows medical experts to provide genetic diagnostics and personalized treatments to their patients. Amir Trabelsi and Moshe Einhorn founded Genoox in 2014, with its headquarters in Palo Alto in California. | $8M / Series B / Feb 01, 2021 | ||
| TailorMed is a health IT company that works with providers, pharmacies and manufacturers to reduce patient financial toxicity and create efficiencies across the patient treatment lifecycle. Our end-to-end platform applies algorithms and automations to make the co-pay assistance and free drug order processes seamless and leverages our deep data setto create actionable insights. | $8M / Series A / Jun 27, 2019 | ||
| The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and our proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale. Our technologies include novel sample preparation methods enablingunprecedented ultra-high enrichment of pathogen DNA for sequencing directly from clinical samples, machine learning algorithms that provide clinically actionable diagnostic results, and a world-class database of WGS and drug efficacy profiles. Day Zero Diagnostics is on a mission to transform the way infectious disease diagnostics are performed by generating the stream of real-time sequencing data required to change how we track, manage and combat infectious diseases.With an enormous unmet clinical and economic need, we are targeting bloodstream infections and sepsis for our first application. The life expectancy of a patient with septic shock is 24 hours without fast effective antibiotic treatment. However, even when successful, current diagnostics take 2-5 days to identify the pathogen AND provide its antibiotic susceptibility profile. The lack of rapid, accurate, and comprehensive diagnostics, forces physicians to “carpet bomb” patients with severe infections with powerful, yet toxic, broad-spectrum antibiotics, which is not only ineffective in many cases but can also lead to significant morbidity and mortality. Day Zero delivers a complete diagnosis, including both the species and antibiotic resistance profile, in hours vs. days, enabling the physician to use a targeted treatment on day zero of hospital admission and resulting in better patient outcomes and cost savings. | $8.6M / Series A / Jan 23, 2019 | ||
| Genoox develops and provides a cloud based big data platform for storing and managing genomic data. Its platform allows medical experts to provide genetic diagnostics and personalized treatments to their patients. Amir Trabelsi and Moshe Einhorn founded Genoox in 2014, with its headquarters in Palo Alto in California. | $6M / Series B / May 15, 2018 | ||
| See all 13 investments → | |||
Co-Investors
About Triventures
Triventures is a global venture capital firm that invests in startups led by exceptional entrepreneurs. The fund identifies cross-industry breakthroughs that converge the best in class in health and non-health technologies such as insurtech and fintech for healthcare, e-commerce and cyber for healthcare, community-driven genomics, health data marketplaces, and more. Triventures’ team is comprised of key opinion leaders in healthcare, entrepreneurship, venturing and corporate business development and has decades of accumulated industry experience and relationships. Triventures was founded in 2010 and is headquartered in Herzliya, Tel Aviv, Israel with offices in California, U.S.
Triventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dr. Peter Fitzgerald
Co-Founder and Managing Partner
|
|||
Michal Geva
Co-Founder and Managing Partner
|
|||
Dani Goldsher
Partner and CFO
|
|||
Martin Leon
Co-Founder and Venture Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Netalie Nadivi invest in?
Netalie Nadivi invests primarily in Health Care, Medical Device and FinTech startups, most often at Series A and Seed stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Netalie Nadivi?
Public channels for Netalie Nadivi include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Netalie Nadivi last invest?
The most recent investment recorded for Netalie Nadivi closed in Apr 2022. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
